Cardiol Therapeutics Inc.
CRDL.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 40.37% | 101.17% | 74.23% | 39.37% | 14.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.92% | 81.64% | 20.35% | 8.30% | -11.93% |
| Operating Income | -20.92% | -81.64% | -20.35% | -8.30% | 11.93% |
| Income Before Tax | -4.08% | -111.08% | 13.40% | -29.90% | -1.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.08% | -111.08% | 13.40% | -29.90% | -1.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.08% | -111.08% | 13.40% | -29.90% | -1.39% |
| EBIT | -20.92% | -81.64% | -20.35% | -8.30% | 11.93% |
| EBITDA | -20.73% | -82.69% | -20.76% | -8.53% | 11.90% |
| EPS Basic | 15.56% | -94.75% | 19.24% | -23.72% | 0.69% |
| Normalized Basic EPS | 15.61% | -95.09% | 19.19% | -23.87% | 0.74% |
| EPS Diluted | 15.56% | -94.75% | 19.24% | -23.72% | 0.69% |
| Normalized Diluted EPS | 15.61% | -95.09% | 19.19% | -23.87% | 0.74% |
| Average Basic Shares Outstanding | 23.39% | 8.30% | 7.25% | 4.94% | 2.10% |
| Average Diluted Shares Outstanding | 23.39% | 8.30% | 7.25% | 4.94% | 2.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |